Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Gastrointestinal 2Sarcoma 1Genitourinary 1Breast 1

Conditions

Mesothelioma 1Lung Neoplasms 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 9Nivolumab 4budigalimab 2belinostat 2Pemetrexed 2Ipilimumab 2Cyclophosphamide 2Cisplatin 2Carboplatin 2venetoclax 1tocilizumab 1tislelizumab 1talazoparib 1spartalizumab 1rovalpituzumab tesirine 1ribociclib 1rebastinib 1obinutuzumab 1naptumomab estafenatox 1fludarabine 1epacadostat 1enzalutamide 1durvalumab 1cabozantinib 1abemaciclib 1Valacyclovir 1Sorafenib 1Sirolimus 1Quality of Life 1Plicamycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma × Plicamycin × Breast × Clear all
NCT01624090 2019-12-30

Mithramycin for Lung, Esophagus, and Other Chest Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
16 enrolled 13 charts
BreastGastrointestinalOther solid neoplasmThoracic

Breast Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡